Transcat (TRNS) Competitors

Cytek Biosciences (NASDAQ:CTKB) and Transcat (NASDAQ:TRNS) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, profitability, analyst recommendations, institutional ownership, dividends and community ranking.

Which has more risk & volatility, CTKB or TRNS?

Cytek Biosciences has a beta of 1.46, meaning that its share price is 46% more volatile than the S&P 500. Comparatively, Transcat has a beta of 0.7, meaning that its share price is 30% less volatile than the S&P 500.

Is CTKB or TRNS more profitable?

Transcat has a net margin of 6.63% compared to Cytek Biosciences' net margin of -5.05%. Transcat's return on equity of 7.36% beat Cytek Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytek Biosciences	-5.05%	-2.58%	-2.05%
Transcat	6.63%	7.36%	5.90%

Which has preferable earnings & valuation, CTKB or TRNS?

Transcat has higher revenue and earnings than Cytek Biosciences. Cytek Biosciences is trading at a lower price-to-earnings ratio than Transcat, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytek Biosciences	$201.21M	4.12	-$12.15M	-$0.08	-80.38
Transcat	$270.61M	3.72	$13.65M	$1.98	55.30

Does the MarketBeat Community favor CTKB or TRNS?

Transcat received 190 more outperform votes than Cytek Biosciences when rated by MarketBeat users. Likewise, 66.88% of users gave Transcat an outperform vote while only 45.45% of users gave Cytek Biosciences an outperform vote.

Company	Underperform	Outperform
Cytek Biosciences	Outperform Votes 20 45.45%	Underperform Votes 24 54.55%
Transcat	Outperform Votes 210 66.88%	Underperform Votes 104 33.12%

Do analysts recommend CTKB or TRNS?

Cytek Biosciences presently has a consensus price target of $9.25, suggesting a potential upside of 43.86%. Transcat has a consensus price target of $130.25, suggesting a potential upside of 18.95%. Given Cytek Biosciences' stronger consensus rating and higher possible upside, equities research analysts plainly believe Cytek Biosciences is more favorable than Transcat.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytek Biosciences	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Transcat	0 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.60

Do institutionals and insiders believe in CTKB or TRNS?

69.5% of Cytek Biosciences shares are owned by institutional investors. Comparatively, 98.3% of Transcat shares are owned by institutional investors. 9.6% of Cytek Biosciences shares are owned by insiders. Comparatively, 2.3% of Transcat shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Does the media favor CTKB or TRNS?

In the previous week, Transcat had 6 more articles in the media than Cytek Biosciences. MarketBeat recorded 9 mentions for Transcat and 3 mentions for Cytek Biosciences. Cytek Biosciences' average media sentiment score of 1.39 beat Transcat's score of 0.17 indicating that Cytek Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cytek Biosciences	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Transcat	1 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Transcat beats Cytek Biosciences on 12 of the 18 factors compared between the two stocks.